BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Coronavirus (COVID-19) » Page 2

Organicell Provides Update on Its COVID-19 Clinical Trial Using Zofin™

November 12, 2020 By Cade Hildreth (CEO)

Organicell Zofin clinical trial
  • Anticipates Phase I/II trial completion by end of year

  • Anticipates Phase IIb trial to begin in Q1 2021

  • Seeks to retain a global contract research organization (“CRO”)

Miami, FL (November 12, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for treatment of COVID-19 using Organicell’s proprietary therapeutic, Zofin™, which is currently underway as well as an update on its expanded access protocol for outpatients with COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19), Exosomes, Press Releases Tagged With: Organicell

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

October 20, 2020 By Cade Hildreth (CEO)

Organicell Zofin heart failure

MIAMI, Oct. 20, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: exosomes, Organicell

ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India

October 11, 2020 By Cade Hildreth (CEO)

Stem cells covid-19 India

ReeLabs received permission from the Central Licensing Authority to conduct the first and only  trial in India using MSCs from placenta and umbilical cord tissue against COVID-19.

There are numerous publications that have documented the role of stem cell against COVID-19. Currently there are 23 stem cell trials in progress in US, UK, Japan, Germany, China, Spain, France and various other developed countries and hitherto published literature is extremely encouraging.

India is now all set to join this elite list. [Read more…]

Filed Under: Cord Blood, Coronavirus (COVID-19)

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment

October 8, 2020 By Cade Hildreth (CEO)

CBR NantKwest COVID

CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy

Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]

Filed Under: Cord Blood, Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: cord blood, cord tissue

FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin(TM)

September 29, 2020 By Cade Hildreth (CEO)

organicell-covid-19-zofin

Miami, FL (September 29, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases Tagged With: COVID-19

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

Stem cell conferences

The Complete Guide To Virtual Stem Cell Conferences in 2021

CO.DON AG

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.